A team of Goodwin Procter attorneys recently advised Jounce Therapeutics, Inc. in the initial closing of its $47 million financing through its issuance and sale of Series A Preferred Stock to Third Rock Ventures.
Jounce is dedicated to transforming the treatment of cancer by focusing on the discovery and development of first-in-class cancer immunotherapies designed to harness the immune system and seek out and attack cancerous cells and tumors. Jounce’s transformational approach has the potential to drive durable responses to treatment, extending and improving patients’ quality of life for years. The company is based in Cambridge, Mass. and was founded by world renowned leaders in the fields of immunobiology, cancer biology, and clinical and translational medicine in cancer.
Founded in 2007, Third Rock Ventures is a venture capital firm with the mission to launch transformative life sciences companies. Third Rock, with more than $800 million in assets under management, is focused on working with passionate entrepreneurs to build exceptional companies in the areas of disruptive science and make a difference in patients’ lives.
The Goodwin team was led by partner Mitchell Bloom.
For additional information regarding the financing, please read the Jounce press release.